A Phase 3, Open Label, Single Arm Study on the Use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs)
Latest Information Update: 20 Apr 2022
At a glance
- Drugs Reteplase (Primary)
- Indications Thrombosis
- Focus Adverse reactions; Registrational
- Acronyms READY 2
- Sponsors Chiesi Farmaceutici
Most Recent Events
- 08 Apr 2022 Planned End Date changed from 1 Aug 2023 to 18 Mar 2022.
- 08 Apr 2022 Planned primary completion date changed from 1 Jan 2023 to 18 Mar 2022.
- 08 Apr 2022 Planned initiation date changed from 1 Mar 2022 to 28 Feb 2022.